You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Assessing the Potential of Gene Therapies for Hemoglobinopathies: The Importance of Long-Term Data

  • Authors: Christine N. Duncan, MD
  • CME / ABIM MOC Released: 1/14/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/14/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for pediatricians, hematologists, and transplant specialists who manage patients with hemoglobinopathies.

The goal of this activity is to improve clinicians' understanding of gene therapies used for hemoglobinopathies and their ability to manage these patients as treatment paradigms evolve.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Historical approaches of gene therapy in hemoglobinopathies
    • Clinical trial data evaluating gene therapies for hemoglobinopathies
  • Have greater competence related to
    • Identifying patients with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) who may benefit from gene therapy
  • Demonstrate greater confidence in their ability to
    • Evaluate the emerging role of gene therapy strategies in the management of patients with hemoglobinopathies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Christine N. Duncan, MD

    Assistant Professor of Pediatrics
    Harvard Medical School
    Medical Director
    Clinical Research and Clinical Development, Gene Therapy Program
    Boston Children's Hospital
    Boston, Massachusetts

    Disclosures

    Disclosure: Christine N. Duncan, MD, has disclosed the following relevant financial relationships:
    Advisor or consultant for: Advanced Clinical; Bluebird Bio

Editor

  • George Boutsalis, PhD

    Director, Content Development, Medscape, LLC

    Disclosures

    Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Assessing the Potential of Gene Therapies for Hemoglobinopathies: The Importance of Long-Term Data

Authors: Christine N. Duncan, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 1/14/2022

Valid for credit through: 1/14/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve clinicians' understanding of gene therapies used for hemoglobinopathies and their ability to manage these patients as treatment paradigms evolve.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print